Members of the The Discovery Club gathered at the Royal Society of Chemistry last month to learn how our research is influencing the cancer patient journey.

Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals.

Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.